Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
ORGANIZATION
Japan Biosimilar Association Says “Authorized Biosimilars” Could Mar Industry Development
The Japan Biosimilar Association issued a statement on May 16, alarming that “authorized biosimilars (AB)” could threaten the healthy development of the biosimilar industry in Japan - a de-facto caution against moves by companies like Kyowa Hakko Kirin, which recently…
To read the full story
Related Article
- MHLW Official Expounds on “Authorized Biosimilar” Pricing, 50% Generic Rule Applies for “Biosame” Products
July 11, 2018
- MHLW Study Group to Issue Report Calling for Guidelines to Promote Efficient Development of Biosimilars
May 18, 2017
- Chugai to Mull Authorized Biosimilars for 3 Key Cancer Meds on “Case-by-Case Basis”
February 2, 2017
- Kyowa Kirin Sets Up New Firm for Nesp Authorized Biosimilar
February 1, 2017
ORGANIZATION
- Kobe, iPark Institute, Partners Sign Pact to Accelerate Innovation at KBIC
January 21, 2026
- OTC Industry Head Urges Caution on Extra Charges for “OTC-Like” Drugs
January 20, 2026
- JETRO Picks 10 Overseas Startups for Regenerative Medicine Japan Entry Program
January 20, 2026
- Pharma FTC Clarifies “Simple Beverages” under New Food Rules
January 14, 2026
- EFPIA Japan Appoints Novartis’ Pullicino as Vice Chair
January 9, 2026
As many as 47 new drug candidates are expected to win approval or secure NHI price listing in Japan in…
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…